First-In-Human Phase 1 Study of ATNM-400, Actinium-225 Antibody Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (EANM 2026) - Sep 29, 2026 - Abstract #OP-525; Pres time: Oct 19, 2026; 04:45 PM - 06:15 PM; Location: Hall G1; "Materials and This phase 1, open-label, dose-escalation study enrolls patients with progressive mCRPC who have received ≥1 androgen-receptor pathway inhibitor and taxane-based chemotherapy; prior ¹⁷⁷Lu-PSMA-617 is permitted but not required. ATNM-400 targets a non-PSMA antigen expressed across PSMA-low and PSMA-negative disease, addressing a critical unmet need in late-line mCRPC. This first-in-human theranostic study will define the safety, PK, biodistribution, and dosimetry profile of ⁸⁹Zr-ATNM-400 to guide therapeutic dosing of ²²⁵Ac-ATNM-400 in ongoing and future cohorts."
First-in-human • Metastases • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
J. Cardaci 1; A. Singh 1; T. Michele 2; N. Lenzo 3; G. Ghosh 3; J. Gibson 4; M. Roy 4; A. Kamal 4; J. Kim 4
|